Monoclonal Antibodies for Oncology Global Market Report 2022


Dublin, July 08, 2022 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies for Oncology: Global Markets" report has been added to's offering.

The current report provides detailed exposure of global monoclonal antibodies for the oncology market. This report highlights the current and future market potential of monoclonal antibodies for oncology treatment and includes a detailed analysis of the market's drivers, challenges, and opportunities.

The report also covers market projections to 2027 and market share for key market players. The report details the market share of monoclonal antibodies for oncology based on type and application. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides the impact of the COVID-19 pandemic on this market.

Report Includes

  • A brief general outlook of the global monoclonal antibodies for oncology market
  • Analyses of the global market trends, with market revenue (sales data) for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Highlights of the current and future market potential of monoclonal antibodies for oncology treatment, and areas of focus to forecast this market into various segments and sub-segments
  • Evaluation of the actual market size for monoclonal antibodies in oncology treatment, forecasted growth trends, and corresponding market share analysis by type of antibody, application area, and region
  • Technology assessment of the key drivers, restraints and opportunities that will shape the market over the next five years (2022 to 2027)
  • In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, major types of end-user markets, and COVID-19 implications on the progress of this market
  • Review of the patent landscape and new developments in the market for monoclonal antibodies for oncology and associated clinical trials
  • Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Monoclonal Antibodies
  • History of Monoclonal Antibodies
  • Advantages and Disadvantages of Monoclonal Antibodies
  • Monoclonal Antibodies in Oncology
  • Types of Monoclonal Antibodies

Chapter 4 Market Dynamics

  • Market Drivers
  • Increasing Incidence of Cancer
  • New Product Launches
  • Rising Healthcare Expenditures and Government Funding
  • Licensing and Collaboration Agreements
  • Market Barriers
  • Price Controls
  • Regulatory Approval Pressures
  • Entry of Biosimilars
  • Opportunities
  • Impact of Covid-19

Chapter 5 Market Breakdown by Type

  • Types of Monoclonal Antibodies for Oncology
  • Market Overview
  • Market Revenue
  • Global Market for Monoclonal Antibodies in Oncology by Type
  • Humanized Monoclonal Antibodies
  • Human Monoclonal Antibodies
  • Chimeric Monoclonal Antibodies

Chapter 6 Market Breakdown by Application

  • Overview
  • Lung Cancer
  • Market Size and Forecast
  • Breast Cancer
  • Market Size and Forecast
  • Colorectal Cancer
  • Market Size and Forecast
  • Blood Cancer
  • Market Size and Forecast
  • Other Cancers
  • Market Size and Forecast

Chapter 7 Market Breakdown by Region

Chapter 8 Regulatory Aspects

  • New Approvals of Monoclonal Antibodies for Oncology
  • Recalls, Withdrawals, and Safety Alerts

Chapter 9 Patent Review/ New Developments

  • New Developments
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Phase III Clinical Trials

Chapter 10 Competitive Landscape

  • Mergers, Acquisitions, and Collaborations
  • Company Market Shares

Companies Mentioned

  • Amgen Inc.
  • AstraZeneca Pharmaceuticals
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Merck Kgaa
  • Pfizer Inc.
  • Sanofi S.A.
  • Seagen

For more information about this report visit


Global Monoclonal Antibodies for Oncology Market